Slingshot members are tracking this event:

GlycoMimetics to Initiate GMI-1271 Myeloma Trials in Mid-2016

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details GlycoMimetics announced that its drug candidate GMI-1271 could reduce chemotherapy resistance from multiple myeloma and that it intends to begin clinical trials in Europe in mid-2016.  The drug, when taken with bortezomib, was shown to reduce chemotherapy resistance to bortezomib and could "improve clinical outcomes for high risk and relapsed patients with myeloma".  GMI-1271 is also currently in a Phase 1/2 study evaluating its safety and efficacy when used with chemotherapy in patients with acute myeloid leukemia (AML).
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 28, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Gmi-1271, Myeloma, Phase 1/2 Trial